NCT03554850|CompletedResultsFDA Device
Loading search results
Sponsor study identifier
observational
201
1 country
10
Study Start
January 30, 2019
Actual (reported)Primary Completion
September 8, 2020
Actual (reported)Study Completion
February 2, 2021
Actual (reported)Trevo® Retriever Registry (China) is to assess real world performance of the FDA cleared Trevo Retriever intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke in China.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2, 2021
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 23, 2018
Actual (reported)June 13, 2018
Actual (reported)January 30, 2019
Actual (reported)September 8, 2020
Actual (reported)February 2, 2021
Actual (reported)January 31, 2022
Actual (reported)the Modified TICI(Thrombolysis in Cerebral Infarction) Scale at the End of Procedure
The primary endpoint is measured using the modified TICI scale at the end of procedure.Success of primary endpoint was defined as a modified TICI score of 2b or better at the end of procedure. Primary endpoint will be analyzed by percentages, frequencies and the 95% confidence interval of the percentage of success. The 95% confidence interval will be calculated using ClopperPearson exact method. Note: Modified TICI score has 6 grades: 0(No Perfusion), 1(Penetration with Minimal Perfusion), 2(Partial Perfusion), 2a(Partial filling with \<50% of the entire vascular territory is visualized), 2b(Partial filling with ≥50% of the entire vascular territory is visualized), 3(Complete Perfusion). Higher scores mean a better outcome.
At the end of the neuro-thrombectomy procedure (Day 1)
Day 90 mRS
Day 90
Day 90 Mortality
Day 90
Neurological Deterioration
24 hours
Rate of Study Device and Procedure Related SAE Through Day 90
Day 90
Stent retriever procedure
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Populations met the inclusion/exclusion criteria above
Beijing TianTan Hospital
Beijing, Beijing Municipality, 100050, China
The Hospital of Shunyi District Beijing
Beijing, Beijing Municipality, 101300, China
Qingyuan City People's Hospital
Qingyuan, Guangdong, 511518, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050051, China
Puyang Oilfield General Hospital
Puyang, Henan, 457001, China
Linyi People's Hospital
Linyi, Shandong, 276003, China
Qingdao Central Hospital
Qingdao, Shandong, 266042, China
ZhongRong Miao, MD
Beijing Tiantan Hospital
201 participants (actual enrollment reported by the registry).
First Submitted
May 23, 2018
First Posted
June 13, 2018
Study Start
January 30, 2019
Actual (reported)Contact the study team to confirm eligibility.
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310016, China
Wenzhou Central Hospital
Wenzhou, Zhejiang, 325000, China
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325027, China
Primary Completion
September 8, 2020
Actual (reported)Study Completion
February 2, 2021
Actual (reported)Last Updated
May 27, 2022
Results First Posted
January 31, 2022
Record last verified: 2022-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: